![Angela Siegling](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Angela Siegling
Chief Tech/Sci/R&D Officer at EUCODIS Bioscience GmbH Deutschland
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Wolfgang Schoenfeld | M | - |
EUCODIS Bioscience GmbH Deutschland
![]() EUCODIS Bioscience GmbH Deutschland Miscellaneous Commercial ServicesCommercial Services EUCODIS GmbH researches and develops products for life science applications. It develops products for life science applications by utilizing vivo recombination and somatic hypermutation technology. The company focuses on development of products such as industrial enzymes, therapeutic proteins, agrochemicals, seed technologies, transgenic animals, biosynthetic pathways and human antibodies. The company was founded in 2004 and is headquartered in Vienna, Austria. | 20 years |
Wolfgang Schüller | M | - |
EUCODIS Bioscience GmbH Deutschland
![]() EUCODIS Bioscience GmbH Deutschland Miscellaneous Commercial ServicesCommercial Services EUCODIS GmbH researches and develops products for life science applications. It develops products for life science applications by utilizing vivo recombination and somatic hypermutation technology. The company focuses on development of products such as industrial enzymes, therapeutic proteins, agrochemicals, seed technologies, transgenic animals, biosynthetic pathways and human antibodies. The company was founded in 2004 and is headquartered in Vienna, Austria. | 18 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Rudy Pandjaitan | M | 54 |
Mixis Genetics Ltd
![]() Mixis Genetics Ltd Pharmaceuticals: OtherHealth Technology Part of Teva Pharmaceutical Industries Ltd., Mixis Genetics Ltd is a French company that develops medicinal chemicals and botanical products. The company is based in Paris, France. The CEO of the company is Gilles Amsallem. Mixis Genetics was acquired by PLIVA dd, part of Teva Pharmaceutical Industries Ltd. from October 24, 2006 on April 01, 1999 for $3.26 million. | - |
Statistics
Country | Connections | % of total |
---|---|---|
Germany | 2 | 66.67% |
France | 1 | 33.33% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Angela Siegling
- Personal Network